Alejandro Hernandez-Sanchez
As a biotechnologist, I started working on the development of a preventive cancer vaccine during my Master´s Thesis at Heidelberg University. I continued research in the field of cancer immunotherapy during my PhD, which I am currently doing at the German Cancer Research Center. My focus is the identification of potential neoantigens that are able to bind to certain HLA Class I alleles, such as HLA-A2, using transgenic models, in vitro assays and advanced competition-based binding assays to MHC class I molecules. These HLA-binding epitopes would be the prime candidates for the development of a preventive vaccine.
“…”